Unlock exclusive insights into the evolving T cell engager landscape
Track the latest developments in TCE research, trials, and therapeutic innovation.
What’s Inside:
- 1,000+ TCE assets tracked – with over 200 in active development
- Record number of Phase 2 trials in 2025 – autoimmune disorder indications gaining pace
- New targets & modalities – CD28, 4-1BB, and co-stimulatory trispecifics emerging
- $100B+ in deals since 2013 – find out which companies are still actively investing
- Global developer landscape – key activity hubs in the US, China, and across Europe
You May Also Be Interested In…
Learn More About Bispecific
- The Most Comprehensive Way to Search the Bispecific Drug Development Landscape: Unique search ontologies based on Bispecific drug and trial characteristics
- Market Leading Approach to Bispecific Preclinical & Clinical Data Curation: Manual curation of key Bispecific research and development data points Bispecific research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search Bispecific company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!
